Bafna Pharmaceuticals Ltd Share Price Bafna Pharma.

3.70

Open ()
Turnover (lac)
Prev. Close ()
Day's Vol.(shares)

4.65

Open ()
Turnover (lac)
Prev. Close ()
Day's Vol.(shares)
Detailed Quote

Corporate Action

Period From
Period To
Purpose AGM Date Announcement Date Book Closure Start Date Book Closure End Date
Board Meeting - 06-Nov-2019 - -
BAFNA PHARMACEUTICALS LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 13/11/2019 ,inter alia, to consider and approve Notice is hereby given that a meeting of the Board of Directors of the Company will be held on Wednesday, 13th November 2019 at the registered office of the Company, to inter alia consider and adopt un-audited financial results for the quarter and six months ended 30th Sep 2019 and any other business with the permission of the Chair
Board Meeting - 01-Aug-2019 - -
BAFNA PHARMACEUTICALS LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 10/08/2019 ,inter alia, to consider and approve Notice is hereby given that a meeting of the Board of Directors of the Company will be held on Saturday, 10th August 2019 at the registered office of the Company, to inter alia consider and adopt un-audited financial results for the first quarter ending 30th June 2019 and fixing of record date for reduction of capital as per resolution plan and authorising directors and company secretary to take necessary steps and any other business with the permission of the Chair. Further in accordance with the Code of Conduct for prevention of Insider Trading pursuant to the SEBI (Prohibition of Insider Trading) Regulations, 2015 the trading window for dealing in securities of the Company shall remain closed until 48 hours after the financial results approved at the meeting are made public. We wish to inform you that pursuant to Regulation 42 of the Securities Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulation, 2015, the Board of Directors of the Company at its meeting held on 10th August, 2019 approved Tuesday, 27th August, 2019 as the RECORD DATE for the purpose of determining the eligible equity shareholders whose equity shares shall stand reduced, pursuant to the Resolution Plan approved by the Honble National Company Law Board Tribunal, Chennai Bench vide its Order dated 1st February, 2019 (Approved Resolution Plan) In terms of the Approved Resolution Plan, the number of Equity Shares existing as on record date shall be reduced to 10%. We would like to inform you that the Board at its meeting held on today approved the following : 1. The un-audited financial results for the first quarter ending 30th June 2019. Please find attached the un-audited financial results for first quarter ending 30th June 2019 along with the Limited Review Report obtained from the statutory auditor of the Company. 2. The Board has approved reconstitution of Audit Committee. The reconstituted Audit Committee composition are as follows: Sl No Name of Director Designation 1 Mr. V. Rajamani Chairman 2 Mr. Babulal Kamlesh Kumar Member 3 Mr. Paras Bafna Member 3. Pursuant to Regulation 42 of the Securities Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulation, 2015, the Board of Directors of the Company approved Tuesday, 27th August, 2019 as the RECORD DATE for capital reduction. We would like to inform you that the Board at its meeting held on today approved the following : 1. The un-audited financial results for the first quarter ending 30th June 2019. Please find attached the un-audited financial results for first quarter ending 30th June 2019 along with the Limited Review Report obtained from the statutory auditor of the Company. 2. The Board has approved reconstitution of Audit Committee. The reconstituted Audit Committee composition are as follows: Sl No Name of Director Designation 1 Mr. V. Rajamani Chairman 2 Mr. Babulal Kamlesh Kumar Member 3 Mr. Paras Bafna Member 3. Pursuant to Regulation 42 of the Securities Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulation, 2015, the Board of Directors of the Company approved Tuesday, 27th August, 2019 as the RECORD DATE for capital reduction. We would like to inform you that the Board at its meeting held on today approved the following : 1. The un-audited financial results for the first quarter ending 30th June 2019. Please find attached the un-audited financial results for first quarter ending 30th June 2019 along with the Limited Review Report obtained from the statutory auditor of the Company. 2. The Board has approved reconstitution of Audit Committee. The reconstituted Audit Committee composition are as follows: Sl No Name of Director Designation 1 Mr. V. Rajamani Chairman 2 Mr. Babulal Kamlesh Kumar Member 3 Mr. Paras Bafna Member 3. Pursuant to Regulation 42 of the Securities Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulation, 2015, the Board of Directors of the Company approved Tuesday, 27th August, 2019 as the RECORD DATE for capital reduction. We wish to inform you that pursuant to Regulation 42 of the Securities Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulation, 2015, the Board of Directors of the Company at its meeting held on 10th August, 2019 approved Tuesday, 27th August, 2019 as the RECORD DATE for the purpose of determining the eligible equity shareholders whose equity shares shall stand reduced, pursuant to the Resolution Plan approved by the Honble National Company Law Board Tribunal, Chennai Bench vide its Order dated 1st February, 2019 (Approved Resolution Plan) In terms of the Approved Resolution Plan, the number of Equity Shares existing as on record date shall be reduced to 10%. (As Per BSE Announcement Dated 10.08.2019)
Board Meeting - 20-May-2019 - -
BAFNA PHARMACEUTICALS LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 27/05/2019 ,inter alia, to consider and approve Notice is hereby given that a meeting of the Board of Directors of the Company will be held on Monday, 27th May 2019 at the registered office of the Company, to inter alia consider and adopt audited financial results for the quarter / year ended 31st March 2019 and any other business with the permission of the Chair. Further in accordance with the Code of Conduct for prevention of Insider Trading pursuant to the SEBI (Prohibition of Insider Trading) Regulations, 2015 the trading window for dealing in securities of the Company shall remain closed until 48 hours after the financial results approved at the meeting are made public. The Board of Directors of the Company at their meeting held on today inter-alia transacted the following business.:- AUDITED FINANCIAL RESULT 1. Approval of audited financial results of the Company for the quarter and year ending 31st March 2019 (standalone and Consolidated). M/s. R. Sathyanarayanan & Co, the Statutory Auditors of the Company have issued Audit Report with modified opinion along with Statement on impact of Modified opinion thereon. Please find enclosed Audited Financial Results, Audit Report, Statement of Assets & Liabilities and Statement on Impact of Modified Opinion thereon.the year ended on March 31, 2019. ANNUAL GENERAL MEETING The 24th Annual General Meeting of the members of the Company is scheduled to be held on 27th June 2019 CLOSURE OF REGISTER OF MEMBERS The Register of members will be closed from 24th June 2019 to 27th June 2019 (both days inclusive) The Board Meeting commenced at 15.30 Hours and concluded at 19.00 Hours. (As Per BSE Announcement Dated on 27/05/2019)
Board Meeting - 31-Jan-2019 - -
BAFNA PHARMACEUTICALS LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 08/02/2019 ,inter alia, to consider and approve Notice is hereby given that a meeting of the Board of Directors of the Company will be held on Friday, 08th February 2019 at the registered office of the Company, to inter alia consider and adopt un-audited financial results for the quarter ended 31st December 2018 and any other business with the permission of the Chair. We would like to inform you that the Board at its meeting held on today approved the un-audited financial results for the Third Quarter ending 31st December 2018. Please find attached the un-audited financial results for Third Quarter ending 31st December 2018 along with the Limited Review Report obtained from the statutory auditor of the Company. Appointment of Mr. Babulal Kamlesh Kumar (DIN: 01218959) as an Independent Director with effect from 08th February 2019 (Annexure-1) The meeting commenced at 3.00 PM and concluded at 6.45 P.M We would like to inform you that the Board at its meeting held on today approved the un-audited financial results for the Third Quarter ending 31st December 2018. Please find attached the un-audited financial results for Third Quarter ending 31st December 2018 along with the Limited Review Report obtained from the statutory auditor of the Company. We would like to inform you that the Board at its meeting held on today approved the un-audited financial results for the Third Quarter ending 31st December 2018. Please find attached the un-audited financial results for Third Quarter ending 31st December 2018 along with the Limited Review Report obtained from the statutory auditor of the Company. Appointment of Mr. Babulal Kamlesh Kumar (DIN: 01218959) as an Independent Director with effect from 08th February 2019 (Annexure-1) The meeting commenced at 3.00 PM and concluded at 6.45 P.M (As Per BSE Announcement Dated 08.02.2019)